VEGFA and pancreatic neoplasm: GCs have been shown to inhibit the growth of patient-derived pancreatic cancer cells using a xenograft model, through the suppression of NF-kB, epithelial-mesenchymal transition (EMT), IL-6, and vascular endothelial growth factor (VEGF) [90].